Roche Holding AG (RHHBF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:49PM EDT
| Previous close | 423.50 |
| Open | 409.75 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 423.50 - 423.50 |
| 52-week range | 340.10 - 473.65 |
| Volume | |
| Avg. volume | 87 |
| Market cap | 275.806B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 22.57 |
| EPS (TTM) | 18.76 |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (2.35%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Zacks
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
- Investing.com
Roche Shares Tick Higher After FDA Approves Influenza Drug in Children 5 and Over
By Scott Kanowsky
- GlobeNewswire
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age The FDA also approved Xofluza to prevent influenza in children aged five years and older following contact with an infected person Basel, 12 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (balo
© 2022 Yahoo. All rights reserved.
